Scarica l'app Stockscreener
3.545
3.35%
0.115
Precedente Chiudi:
$3.43
Aprire:
$3.35
Volume 24 ore:
15,990
Relative Volume:
2.23
Capitalizzazione di mercato:
$24.12M
Reddito:
-
Utile/perdita netta:
$-23.87M
Rapporto P/E:
-0.0977
EPS:
-36.3
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
-0.14%
1M Prestazione:
+2.75%
6M Prestazione:
-23.84%
1 anno Prestazione:
-10.25%
Intervallo 1D:
$3.35
$3.62
Intervallo di 1 settimana:
$3.225
$3.62
Portata 52W:
$2.95
$9.20
Polypid Ltd Stock (PYPD) Company Profile
Confronta PYPD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| PYPD | 3.545 | 24.12M | 0 | -23.87M | -47.63M | -36.30 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-07-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Iniziato | Alliance Global Partners | Buy |
| 2020-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2020-07-21 | Iniziato | Barclays | Overweight |
| 2020-07-21 | Iniziato | Raymond James | Outperform |
Mostra tutto
Polypid Ltd Borsa (PYPD) Ultime notizie
PolyPid Ltd. (NASDAQ:PYPD) Q3 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
PolyPid Reports Q3 Results Amid SHIELD II Trial Progress - TipRanks
PolyPid Announces SHIELD II Trial Progress and Financials - TipRanks
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
PolyPid (PYPD) to Release Earnings on Wednesday - Defense World
PolyPid Announces $8.25 Million Share Sale Plan - TipRanks
PYPDPolyPid Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference - StockTitan
Craig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - MSN
PolyPid shares rise on strong Phase 3 prospects, gets buy rating - Investing.com Canada
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 - GlobeNewswire
Will PolyPid Wield The SHIELD? - RTTNews
Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd - GuruFocus.com
PolyPid Announces Publication in International Journal of - GlobeNewswire
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery - StockTitan
PolyPid retains stock target, buy rating on positive trial enrollment update By Investing.com - Investing.com South Africa
PolyPid retains stock target, buy rating on positive trial enrollment update - Investing.com India
PolyPid completes enrollment for phase 3 trial - Investing.com
PolyPid Nears Completion of Key Phase 3 Trial - TipRanks
PolyPid Announces Last Patient In for Planned Unblinded - GlobeNewswire
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - StockTitan
PolyPid to Participate in Three Upcoming Fall Investor Conferences - GlobeNewswire
Equities Analysts Offer Predictions for PolyPid Ltd.’s Q3 2024 Earnings (NASDAQ:PYPD) - Defense World
HC Wainwright Reiterates “Buy” Rating for PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: PolyPid reports a net loss of $6.3 million in the second-quarter of 2024 - Investing.com
PolyPid Reports Growth in Mid-Year Assets - TipRanks
PolyPid Advances SHIELD II Trial with Solid Financing - TipRanks
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results - GlobeNewswire
Analyzing Silk Road Medical (NASDAQ:SILK) & PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (PYPD) Scheduled to Post Earnings on Wednesday - Defense World
PolyPid secures $14 million in private placement - Investing.com
PolyPid secures $14 million in private placement By Investing.com - Investing.com UK
PolyPid Secures Funding, Extends Runway for D-PLEX100 Trial - TipRanks
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds - StockTitan
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 - GlobeNewswire
PolyPid stock hits 52-week low at $3.35 amid market challenges - Investing.com
Polypid Ltd Azioni (PYPD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):